Brinzolamide is indicated to decrease elevated intraocular pressure in ocular hypertension or open-angle glaucoma as monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues.
For this indication, competent medicine agencies globally authorize below treatments:
For: Adults (18-64) Elders (65+)
Ophthalmic, 1 drops, 2 to 3 times daily.
When used as monotherapy or adjunctive therapy, the dose is one drop in the conjunctival sac of the affected eye(s) twice daily. Some patients may have a better response with one drop three times a day.
Nasolacrimal occlusion or gently closing the eyelid after instillation is recommended. This may reduce the systemic absorption of medicinal products administered via the ocular route and result in a decrease in systemic side effects.
When substituting another ophthalmic antiglaucoma agent with brinzolamide, discontinue the other agent and start the following day with brinzolamide.
If more than one topical ophthalmic medicinal product is being used, the medicines must be administered at least 5 minutes apart. Eye ointments should be administered last.
If a dose is missed, treatment should be continued with the next dose as planned. The dose should not exceed one drop in the affected eye(s) three times daily.